KLRA Kailera Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2096997 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets4.7%
Debt / equity0.00x
Current ratio21.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $84.67M | $101.06M | $70.87M | $26.99M | $19.52M | $10.13M |
| SG&A expense | $21.67M | $20.31M | $13.79M | $13.12M | $11.13M | $10.33M |
| Operating income | -$106.34M | -$121.37M | -$84.66M | -$40.11M | -$30.65M | -$20.46M |
| Net income | -$95.67M | -$111.31M | -$78.86M | -$39.62M | -$28.95M | -$17.98M |
| EBITDA | -$106.23M | -$121.27M | -$84.56M | -$40.05M | -$30.59M | -$20.39M |
| EPS (basic) | -0.74 | -1.09 | -3,650.00 | -39,623.00 | -28,947.00 | -17,983.00 |
| EPS (diluted) | -0.74 | -1.09 | -3,650.00 | -39,623.00 | -28,947.00 | -17,983.00 |
| Weighted avg. shares (diluted) | 129.65M | 102.23M | 21,607 | 1 | 1 | 1 |
| Balance sheet | ||||||
| Cash & equivalents | $106.54M | $130.30M | $111.83M | $97.91M | $101.37M | $101.78M |
| Short-term investments | $794.92M | $786.44M | $407.35M | — | — | — |
| Current assets | $919.76M | $929.17M | $530.32M | — | — | — |
| PP&E, net | $1.65M | $1.75M | $1.85M | — | — | — |
| Total assets | $1.08B | $1.21B | $624.76M | — | — | — |
| Current liabilities | $42.12M | $83.65M | $54.84M | — | — | — |
| Total liabilities | $51.06M | $92.95M | $64.48M | — | — | — |
| Shareholders' equity | $1.03B | $1.12B | -$432.09M | -$297.88M | -$262.58M | -$235.24M |
| Shares outstanding | 129.68M | 129.62M | 29,953 | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$133.67M | -$77.53M | -$68.31M | -$29.70M | -$26.23M | -$18.20M |
| Investing cash flow | $110.83M | -$571.02M | $22.85M | $26.48M | -$74.17M | -$54.44M |
| Financing cash flow | -$922,000 | $667.03M | -$2.98M | -$243,000 | $100.00M | $0 |
| Depreciation & amortization | $101,000 | $101,000 | $101,000 | $63,000 | $62,000 | $63,000 |
| Stock-based compensation | $9.92M | $8.34M | $3.94M | $4.27M | $1.63M | $1.52M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.